Liraglutide regulatory status

FDA and compounding

FDA approved products (Victoza January 2010, Saxenda December 2014). FDA approved the first generic liraglutide referencing Victoza in December 2024, and generic products referencing Saxenda followed in 2025, so branded, generic, and authorized generic pens are all on the market. FDA listed liraglutide injection as in shortage in its October 2024 and February 2025 GLP-1 updates, and FDA's Drug Shortages database still lists it as of September 27, 2026 (first posted July 18, 2023; updated September 22, 2026), with Victoza and Saxenda presentations at limited availability and unbranded presentations available. FDA states that a compounded drug may not be identical or nearly identical to an FDA-approved drug unless the approved drug is on FDA's drug shortage list. On April 30, 2026 FDA proposed not to include liraglutide on the 503B bulks list; that proposal was not final as of September 2026. Ask any pharmacy offering compounded liraglutide which FDA rule it relies on.

WADA

Not WADA prohibited

Access path

1. Prescription from a licensed provider (in person or telehealth) filled at a retail pharmacy as Victoza, Saxenda, or generic liraglutide.
2. Compounded liraglutide: FDA's Drug Shortages database lists liraglutide injection as in shortage as of September 27, 2026, and FDA states that the limit on compounding essentially a copy of an approved drug does not apply to drugs on that list. Generic liraglutide is also marketed. Ask any pharmacy offering compounded liraglutide which FDA rule it relies on.
3. FDA's Drug Shortages database lists Saxenda (NDC 0169-2800-15) as To Be Discontinued, posted August 25, 2026.
4. Products labeled research use only are not lawful for human use.

Full Liraglutide page: evidence, dosing in the literature, and sources